Open Access

The effect of IL-13 and IL-13R130Q, a naturally occurring IL-13 polymorphism, on the gene expression of human airway smooth muscle cells

Respiratory Research20056:9

DOI: 10.1186/1465-9921-6-9

Received: 08 December 2004

Accepted: 20 January 2005

Published: 20 January 2005

Abstract

Background

Growing evidence shows that interleukin 13 (IL-13) may play an essential role in the development of airway inflammation and bronchial hyper-responsiveness (BHR), two defining features of asthma. Although the underlying mechanisms remain unknown, a number of reports have shown that IL-13 may exert its deleterious effects in asthma by directly acting on airway resident cells, including epithelial cells and airway smooth muscle cells. In this report, we hypothesize that IL-13 may participate in the pathogenesis of asthma by activating a set of "pro-asthmatic" genes in airway smooth muscle (ASM) cells.

Methods

Microarray technology was used to study the modulation of gene expression of airway smooth muscle by IL-13 and IL-13R130Q. TaqMan™ Real Time PCR and flow cytometry was used to validate the gene array data.

Results

IL-13 and the IL-13 polymorphism IL-13R130Q (Arg130Gln), recently associated with allergic asthma, seem to modulate the same set of genes, which encode many potentially interesting proteins including vascular cellular adhesion molecule (VCAM)-1, IL-13Rα2, Tenascin C and Histamine Receptor H1, that may be relevant for the pathogenesis of asthma.

Conclusions

The data supports the hypothesis that gene modulation by IL-13 in ASM may be essential for the events leading to the development of allergic asthma.

Background

Recent reports using murine models of allergic asthma have shown that the Th2 type cytokine IL-13 may play a critical role in the pathogenesis of asthma, either by regulating airway inflammation, mucus hyper-secretion or airway hyper-responsiveness [15]. Evidence suggests that the potential role of IL-13 in asthma may come from its aptitude to directly interact with airway resident cells, such as epithelial cells or airway smooth muscle (ASM) cells, as shown by the ability of IL-13 to stimulate a set of different pro-asthmatic genes including inflammatory cytokines such as thymus and activation-regulated chemokine (TARC), eotaxin, monocyte chemotactic protein-1 (MCP-1) as well as growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) [610]. The ability of IL-13 to modulate ASM responsiveness to G-protein coupled receptor (GPCR) agonists, either by increasing contractile agonist-evoked calcium responses [11], and/or by impairing ASM responsiveness to β2-adrenoceptor stimulation [6], may also explain, at least in part, the putative role of IL-13 in allergen-associated BHR reported in animal models [14]. Previous reports have shown that other cytokines such as tumor necrosis factor alpha (TNFα) or interleukin (IL)-1β, may also participate in airway hyper-responsiveness by modulating ASM responsiveness to contractile GPCR agonists [1214]. These data strongly support the current concept that cytokine modulation of ASM, an effector cell thought to solely regulate bronchomotor tone [12], may play an important role in the development of airway inflammation and bronchial hyper-responsiveness, the two main features of asthma. The molecular mechanisms by which IL-13 induces "pro-asthmatic responses" in ASM have not been clearly established. Identifying the expression profile of "pro-asthmatic" genes activated by IL-13 in ASM cells may therefore provide new insight into the design of novel therapeutic approaches for asthma.

Using complementary molecular approaches, we investigated the effect of IL-13 on the transcription of "pro-asthmatic" genes in human airway smooth muscle cells (HASMC). The effect of IL-13 was compared to that of IL-13R130Q, a naturally occurring isoform resulting in a change from glutamine to arginine residues in the coding region that is associated with high serum IgE levels [15]. Interestingly, no report has yet investigated whether both IL-13 and IL-13R130Q share the same or have different biological activities. We found that both IL-13 and IL-13R130Q stimulate the same set of important genes that encode for proteins which may be clinically relevant for regulating airway hyper-responsiveness, airway inflammation and airway remodeling, key characteristics of asthma.

Methods

Cell Culture

Human tracheas were obtained from lung transplant donors, in accordance with procedures approved by the University of Pennsylvania Committee on Studies Involving Human Beings. A segment of trachea just proximal to the carina was removed under sterile conditions and the tracheal muscle was isolated. The muscle was then centrifuged and resuspended in 10 ml of buffer containing 0.2 mM CaCl2, 640 U/ml collagenase, 1 mg/ml soybean trypsin inhibitor and 10 U/ml elastase. Enzymatic dissociation of the tissue was performed for 90 min in a shaking water bath at 37°C. The cell suspension was filtered through 105 μm Nytex mesh, and the filtrate was washed with equal volumes of cold Ham's F12 medium (Gibco BRL Life Technologies, Grand Island, NY) supplemented with 10% FBS (HyClone, Logan, UT) 100 U/ml penicillin (Gibco), 0.1 mg/ml streptomycin (Gibco), and 2.5 μg/ml fungizone (Gibco). Aliquots of the cell suspension were plated at a density of 1.0 × 104 cells/cm2. The cells were cultured in Ham's F12 media supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin and this was replaced every 72 h. Human ASM cells in subculture during the second through to fifth cell passages were used because, during these cell passages, the cells retain native contractile protein expression, as demonstrated by immunocytochemical staining for smooth muscle actin and myosin [16]. Unless otherwise specified, all chemicals used in this study were purchased from Sigma/Aldrich (St. Louis, MO).

RNA isolation

Total cellular RNA was isolated from IL-13 (50 ng/ml), IL-13R130Q (50 ng/ml) or control treated HASMC using the RNeasy mini kit (Qiagen, Inc. Valencia, CA) as per manufacturer's instructions. The IL-13 was purchased from R&D Systems (Minneapolis, MN) and the IL-13R130Q was generated in house at Centocor Inc. The quality and quantity of RNA was assessed using the Agilent 2100 Bioanalyzer (South Plainfield, New Jersey). Samples that demonstrated high quality (ratio of 28S rRNA and 18S rRNA is greater than 1.7) were submitted for microarray analysis.

Microarray Processing

A complimentary DNA (cDNA) microarray, or DNA chip (Target B), containing a total of 8159 human gene cDNA clones from Research Genetics (IMAGE consortium, Huntsville, AL), Incyte Genomics (Santa Clara, CA) and internal sources was used in this study. All clones have been verified by DNA sequencing and are printed as 2 independent spots on a given chip. Duplicate chips were used for each RNA sample. Non-linear normalization between duplicate chips allowed each clone to be averaged to a single intensity value for each RNA sample.

RNA amplification, probe synthesis and labeling, cDNA chip hybridization and washing were performed as described previously [17]. Agilent Image Scanner was used to scan the cDNA chips (Agilent Technologies, Palo Alto, CA). Fluorescence intensity for each feature of the array was obtained by using ImaGene software (BioDiscovery, Los Angeles, CA).

Microarray data analysis

In this study, fifty one-color cDNA microarrays were used to profile gene expression in human airway smooth muscle cells from 3 donors stimulated with IL-13, or its variant IL-13R130Q at 2 time points (6 hr and 18 hr). Untreated samples from the same group of donors were used as control. The samples being analyzed are listed in Table 1.
Table 1

Summary of number of samples from each donor and treatments

Time

Donor

Untreated

IL-13

IL-13R130Q

6 hr

Donor 1*

-

-

-

 

Donor 2

1

2

2

 

Donor 3

1

2

2

18 hr

Donor 1

1

2

2

 

Donor 2

1

2

2

 

Donor 3

1

2

2

*The samples from Donor 1 at the 6 hr time point were not included due to poor quality of RNA.

Purified cDNA probes were hybridized to two microarrays, each containing two spots for each cDNA. Raw intensity data from the cDNA arrays were first normalized within each sample. Linear normalization and then nonlinear normalization was performed within each sample. Outlier intensity data points (greater than 1.4 fold away from the median of replicate measurements) were identified and removed from the data sets. The average intensity was generated by calculating the arithmetic mean of nonoutlier intensity values. The averaged intensity for each clone was further normalized across all samples. Chip-to-chip normalization was performed by dividing the averaged intensity of each clone by the 50.0th percentile of all measurements in that sample. The intensity of each clone was then normalized to the median intensity of that clone in the untreated control group. The normalized intensity was then log transformed.

Using Partek Pro™ 5.1, sources of variance, such as batch effects, were identified by Principle Component Analysis (PCA) and appropriate factors were taken into account in the Analysis of Variance (ANOVA). ANOVA was performed to identify the genes that were differentially expressed by cytokine stimulation. Treatment (IL-13 and IL-13R130Q), time (6 hour and 18 hour), and donor (1, 2, and 3) were the three main effects considered in ANOVA. P-value cutoff was 0.05.

Benjamini and Hochberg false discovery rate (FDR) was performed for multiple testing correction. After comparing the gene lists from IL-13 and IL-13R130Q treatments, it was clear that these two treatments resulted in the regulation of the same set of genes. Subsequently, samples from these two treatments were combined and regarded as replicates in ANOVA. Furthermore, outliner samples in the data set were detected by PCA and removed to improve the detection power.

As an alternative approach, fold change comparisons (cutoff = 1.5 fold) between a treated condition and the control were carried out within each donor by using GeneSpring™ 6.2 [18]. A gene was considered as reliably detected in a given condition if more than half of the replicates representing the same condition had a raw expression intensity of more than 50, CV smaller than 25%, and raw intensity being generated from 2 or more of the duplicate spots representing the clone. A pair-wise comparison between a treatment and its untreated control was performed only on the genes that were reliably detected in at least one condition of the pair. The genes that showed at least 1.5 fold differential expression in two or more donors were identified for each cytokine treatment at a time.

Reverse Transcription and Real Time PCR

1 μg of total RNA from each of the IL-13 (50 ng/ml) or IL-13R130Q (50 ng/ml) or control treated HASMC were used for the reverse transcription (RT) reaction. The RT reaction was performed as per protocol using TaqMan® RT reagents (Applied Biosystems) at 37°C for 120 min followed by 25°C for 10 min. Forty ng of cDNA per reaction were used in the Real Time PCR using the ABI Prism® 7900 sequence detection system (Foster City, California). In the presence of AmpliTaq Gold DNA plolymerase (ABI biosystem, Foster City, California), the reaction was incubated for 2 min at 50°C followed by 10 min at 95°C. Then the reaction was run for 40 cycles at 15 sec, 95°C and 1 min, 60°C per cycle. Assays-on-Demand™ primers and probes (Applied Biosystems) were used in the PCR. The Real Time PCR data was analyzed using the standard curve method.

Flow Cytometry

Flow cytometry was performed as described previously with slight modifications [19]. Briefly, adherent cells treated with IL-13 for 24 hr were washed with PBS, detached by trypsinization (2 min, 37°C) and then washed with Ham's-F12 (10% FCS) media, centrifuged, and transferred to microfuge tubes (1.5 ml). Cells were incubated with anti-IL-13Rα2 (5 μg/ml, Santa Cruz Biotech) antibody followed by 1 hr incubation with a fluorescein isothiocyanate-conjugated secondary antibody (Jackson ImmunoResearch Laboratories; West Grove, PA). In parallel experiements, cells were incubated with the FITC-conjugated mouse anti-VCAM-1 antibody (2 μg/ml, Santa Cruz Biotech) for 1 h at 4°C. The cells were then centrifuged and resuspended in cold PBS in microfuge tubes. Samples were then analyzed using an EPICS XL flow cytometer (Coulter, Hialeah, FL). VCAM-1 and IL-13Rα2 levels were expressed as the increase in mean fluorescence intensity over un-stimulated cells.

Results

IL-13 regulates gene expression of HASMCs

IL-13 may exert its deleterious effects in asthma by directly altering gene expression in airway resident cells such as epithelial cells or ASM cells [57, 20]. In order to determine which genes are regulated by IL-13 in airway smooth muscle cells, we employed the cDNA microarray technology. We also wanted to ascertain if the effect of IL-13R130Q, a naturally occurring isoform of IL-13 and associated with high serum IgE levels [15], was any different than IL-13 in terms of modulating gene expression. The concentrations of IL-13 (10–100 ng/ml) used in our study were shown previously to stimulate gene expression in human ASM cells [7, 8, 10], although the in vivo relevance of these particular concentrations remains unknown.

Three donors were used and two types of analyses were carried out (Fold change analysis; Statistical Analysis). Both IL-13 and IL-13R130Q generated a similar expression profile i.e., genes regulated by IL-13 were the same as those regulated by IL-13R130Q at the 1.5 fold cutoff. Table 2 lists genes of interest that were identified from analyzing the data and divides them into one of three categories. Genes involved in all three characteristics of asthma (airway inflammation, remodeling and bronchial hyper-responsiveness) were identified. Of particular interest are vascular cellular adhesion molecule (VCAM)-1, Tenascin C, IL-13Rα2 and Histamine Receptor H1.
Table 2

Summary of genes up regulated by IL-13 and IL-13R130Q.

Category

Gene(s)

Fold change

Airway Inflammation

  

Adhesion Molecules

VCAM-1

2 fold

 

ALCAM

 
 

Selectin P ligand

 
 

Laminin B1

 

Chemokines

Chemokine Ligand 2

 
 

Chemokine Ligand 11

 
 

Chemokine Ligand 26

 
 

Chemokine Ligand 27

 

Cytokine receptors

IL-13 Rα2

1.6 fold

 

Interleukin 1 receptor

 

Airway Remodeling

  

Extracellular matrix

Tenascin C

2 fold

 

Tenascin R

 
 

Collagen Type I

 
 

Collagen Type VI

 
 

Collagen Type III

 
 

Fibulin 1

 
 

CD44

 

Cell proliferation

Pim-1

 
 

eEF1A

 

Cytokines

PDGFC

 
 

Retinoic acid Receptor

 
 

Interferon beta 1

 

Bronchial Hyper-responsiveness

  

Cytoskeletal constituants

Vimentin

 
 

Tropomyosin 1

 
 

Tropomyosin 2

 
 

Actin

 

Calcium regulators

Phospholipase D

 
 

Calreticulin

 
 

hGIRK1

 
 

TRPC4

 
 

TRPC6

 
 

Sphingosine kinase 1

 
 

Rho GDP dissociation inhibitor

 
 

FKBP1A

 

Receptor

Histamine H1 receptor

1.3 fold

The fold changes correspond to the genes in bold.

Real Time PCR validation

TaqMan™ Real Time PCR was used to validate VCAM1, IL-13Rα2, Tenascin C and Histamine Receptor H1. As shown in Figure 1A, VCAM1 was upregulated between 2 and 2.5 fold upon IL-13 or IL-13R130Q treatment at the 6 and 18 hour time points in both donors. This is comparable to the microarray data (Table 2). In Figure 1B, IL-13Rα2 mRNA is upregulated with IL-13 or IL-13R130Q. However, the upregulation is more pronounced at the 18 hour time point compared to 6 hour. In Figure 2A Tenascin C is upregulated with IL-13 and IL-13R130Q and in Figure 2B, Histamine Receptor H1 shows an upregulation of about 1.5 fold in both donors at both time points and with both treatments. Again, this is comparable to the microarray data (Table 2).
Figure 1

Real Time PCR (Taqman®) analysis showing the level of A) VCAM1 B) IL-13Rα2 upon treatment of ASM from two donors with IL-13 or IL-13R13Q for 6 or 18 hrs. The quantity of each gene is normalized to 18S and relative to the untreated sample. Values shown are mean ± standard deviation from an n = 6.

Figure 2

Real Time PCR (Taqman®) analysis showing the level of A) Tenascin C and B) Histamine receptor H1 upon treatment of ASM from two donors with IL-13 or IL-13R13Q for 6 or 18 hrs. The quantity of each gene is normalized to 18S and relative to the untreated sample. Values shown are mean ± standard deviation from an n = 6.

Validation of VCAM-1 and IL-13Rα2 at the protein level

In order to validate the modulatory effect of IL-13 on VCAM-1 and IL-13Rα2 genes at their protein level, flow cytometry was performed to confirm the up regulation of VCAM-1 and IL-13Rα2 in HASMC by IL-13. As shown in Figure 3 and 4, IL-13 (10–100 ng/ml, 24 hr) differentially stimulates the expression of VCAM-1, with levels increasing in a dose-dependent manner, while IL-13Rα2 levels were identical at 10, 30 and 50 ng/ml. At 100 ng/ml IL-13, VCAM-1 and IL-13Rα2 levels were significantly increased by 20% and 35% over basal, respectively (n = 3, p < 0.05). Increases in VCAM-1 and IL-13Rα2 proteins by IL-13 nicely correlate with changes in mRNA levels (Figure 1A and Figure 1B), suggesting that the IL-13 regulates the expression of inflammatory proteins via transcriptional mechanisms.
Figure 3

Effect of IL-13 on VCAM-1 expression. ASM cells were incubated with the indicated concentrations of IL-13 for 24 hr. VCAM-1 expression was assessed by flow cytometry as described in Methods. Values shown are mean ± SEM and are significantly different from basal, n = 3 different experiments. *P < 0.05 significant from untreated cell.

Figure 4

Effect of IL-13 on IL-13Rα2 expression. ASM cells were incubated with the indicated concentrations of IL-13 for 24 hr. IL-13Rα2 expression was assessed by flow cytometry as described in Methods. Values shown are mean ± SEM and are significantly different from basal, n = 3 different experiments. *P < 0.05 significant from untreated cell.

Discussion

Recent evidence using various experimental approaches such as gene-deficient mice, soluble inhibitors or transgene overexpressing IL-13 in the airways have highlighted the critical role of IL-13 in the pathogenesis of allergic asthma, possibly due to its ability to regulate goblet cell metaplasia, mucus hypersecretion and airway hyper-responsiveness [1, 3, 21]. Few reports that used microarray analyses applied to cultured human ASM cells demonstrated that IL-13 differentially regulates a number of important genes that are relevant for the pathogenesis of asthma [7, 10]. Although the functional relevance of such gene microarray analyses remains yet uncertain, these studies strongly suggest that IL-13 may be involved in the pathogenesis of asthma by directly modulating physiological responses of the ASM. Compared to the previous gene microarray reports [7, 10], we did confirm the physiological relevance of the microarray data using two different experimental approaches. At least for four different genes, VCAM-1 (an adhesion protein), IL-13Rα2, Histamine H1 receptor (a G protein-coupled receptor) and Tenascin C (an extracellular matrix glycoprotein), there was a close correlation between the data obtained from gene microarray with those obtained by real time PCR analyses. In addition, we showed that IL-13 stimulates the expression of VCAM-1 and IL-13Rα2 at the protein level, showing the physiological relevance of the gene array data. It is interesting to note that no difference in gene expression profile were noticeable between cells exposed to IL-13 or IL-13R130Q, an IL-13 polymorphism recently found to be associated with elevated serum and allergen-specific IgE [15, 22]. Our report is the first to suggest that this particular IL-13 polymorphism is equally effective as IL-13 in the transcriptional regulation of the genes examined in the present study.

Our present study further supports the concept that IL-13 regulates the expression of different "pro-asthmatic" genes that are potentially important in the regulation of all three key features of asthma, i.e., airway inflammation, airway remodeling and bronchial hyper-responsiveness (for details see Table 2). Previous reports using cultured ASM cells also demonstrated that IL-13 can stimulate the expression of other pro-inflammatory proteins, such as eotaxin [8, 23, 24], TARC [9] or VEGF [25] and tenascin [present report and [10]]. Upregulation of tenascin C and R, glycoproteins that contribute to extracellular matrix structure [26], may play an important role in airway remodeling, a characteristic of chronic asthma. The stimulatory role of IL-13 on VCAM-1 may be important in asthma since VCAM-1 has been regarded as a key player in the development of airway inflammation [27]. The ability of IL-13 to increase the expression of different G-protein coupled receptors (GPCR), such as Histamine H1 [present report and [10]] or CysLT1 receptor [28] represents one potential mechanism by which IL-13 promotes airway hyper-responsiveness to GPCR agonists previously described both in vivo [1, 3, 21] or in vitro in isolated airways preparations [11, 29, 30]. Additional studies are needed to determine whether IL-13 also modulates ASM responsiveness to Histamine.

The receptor complex by which IL-13 regulates cellular function comprises the IL-13Rα1, which binds IL-13 and forms a complex with the IL-4Rα to initiate signal transduction via the JAK/STAT6 pathway [31]. IL-13Rα2, the other cell surface protein binds IL-13 with high affinity but the complex is not functionally active. One previous report using transgenic mice showed that overexpressing IL-13 in the airways induced a marked increase in both IL-13Rα1 and IL-13Rα2 mRNA levels, mostly in epithelial cells and macrophages [32]. Our study is the first to show that the expression of IL-13Rα2 is also transcriptionally increased by IL-13 in ASM cells. Although the functional significance of such regulation remains unknown, it is possible that the newly induced IL-13Rα2 could function as a decoy receptor to limit IL-13 signaling in ASM cells. Additional studies are needed to further support this hypothesis.

Conclusions

These data further support the hypothesis that gene modulation by IL-13 in ASM may be essential for the events leading to the development of allergic asthma. Additional studies are clearly needed to define the transcriptional regulation of the different "pro-asthmatic" genes by IL-13, which may lead to novel therapeutic approaches for the treatment of allergic asthma.

Declarations

Acknowledgements

This study was supported through grants from the National Institutes of Health (RO1-HL55301 to RAP and 2RO1-HL064063 to YA), and American Lung Association grant RG-062-N (YA). Yassine Amrani is a Parker B. Francis Fellow in Pulmonary Research.

Authors’ Affiliations

(1)
Centocor Inc.
(2)
Pulmonary Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania

References

  1. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB: Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998, 282:2261–2263.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, Taniguchi M, Grusby MJ, DeKruyff RH, Umetsu DT: Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003, 9:582–588.View ArticlePubMedGoogle Scholar
  3. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD: Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258–2261.View ArticlePubMedGoogle Scholar
  4. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyff RH, Umetsu DT: Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001, 167:4668–4675.View ArticlePubMedGoogle Scholar
  5. Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, Erle DJ: The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002, 26:202–208.View ArticlePubMedGoogle Scholar
  6. Laporte JC, Moore PE, Baraldo S, Jouvin MH, Church TL, Schwartzman IN, Panettieri RA Jr, Kinet JP, Shore SA: Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med 2001, 164:141–148.View ArticlePubMedGoogle Scholar
  7. Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ, Sheppard D: Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol 2001, 25:474–485.View ArticlePubMedGoogle Scholar
  8. Hirst SJ, Hallsworth MP, Peng Q, Lee TH: Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain. Am J Respir Crit Care Med 2002, 165:1161–1171.View ArticlePubMedGoogle Scholar
  9. Faffe DS, Whitehead T, Moore PE, Baraldo S, Flynt L, Bourgeois K, Panettieri RA, Shore SA: IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype. Am J Physiol Lung Cell Mol Physiol 2003, 285:L907-L914.View ArticlePubMedGoogle Scholar
  10. Jarai G, Sukkar M, Garrett S, Duroudier N, Westwick J, Adcock I, Chung KF: Effects of interleukin-1beta, interleukin-13 and transforming growth factor-beta on gene expression in human airway smooth muscle using gene microarrays. Eur J Pharmacol 2004, 497:255–265.View ArticlePubMedGoogle Scholar
  11. Tliba O, Deshpande D, Chen H, Van Besien C, Kannan M, Panettieri RA Jr, Amrani Y: IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 2003, 140:1159–1162.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Amrani Y, Panettieri RA Jr: Modulation of calcium homeostasis as a mechanism for altering smooth muscle responsiveness in asthma. Curr Opin Allergy Clin Immunol 2002, 2:39–45.View ArticlePubMedGoogle Scholar
  13. Deshpande DA, Walseth TF, Panettieri RA, Kannan MS: CD38-cyclic ADP-ribose-mediated Ca2+ signaling contributes to airway smooth muscle hyperresponsiveness. Faseb J 2003, 3:452–454.Google Scholar
  14. Hunter I, Cobban HJ, Vandenabeele P, MacEwan DJ, Nixon GF: Tumor Necrosis Factor-alpha-Induced Activation of RhoA in Airway Smooth Muscle Cells: Role in the Ca(2+) Sensitization of Myosin Light Chain(20) Phosphorylation. Mol Pharmacol 2003, 63:714–721.View ArticlePubMedGoogle Scholar
  15. Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsch C, Weiland SK, Erickson RP, von Mutius E, Martinez FD: A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000, 105:506–513.View ArticlePubMedGoogle Scholar
  16. Panettieri RA, Murray RK, DePalo LR, Yadvish PA, Kotlikoff MI: A human airway smooth muscle cell line that retains physiological responsiveness. Am J Physiol 1989, 256:C329-C335.PubMedGoogle Scholar
  17. Salunga RG, Guo H, Luo L, Bittner A, Joy KC, Chambers J, Wan J, Jackson MR, Erlander MG: Gene expression analysis via cDNA microarray of laser capture microdissected cells from fixed tissue. In DNA microarrays a practical approach. Edited by: Schena M. Oxford University Press, Oxford; 1999.Google Scholar
  18. Conway AR: GeneSpring version 6.2 Silicon Genetics, Redwood City, CA. 2004.Google Scholar
  19. Amrani Y, Lazaar AL, Panettieri RA Jr: Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-kappa B-dependent signaling pathway that is only partially sensitive to dexamethasone. J Immunol 1999, 163:2128–2134.PubMedGoogle Scholar
  20. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, Elias JA, Sheppard D, Erle DJ: Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002, 8:885–889.PubMedGoogle Scholar
  21. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779–88.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Leung TF, Tang NL, Chan IH, Li AM, Ha G, Lam CW: A polymorphism in the coding region of interleukin-13 gene is associated with atopy but not asthma in Chinese children. Clin Exp Allergy 2001, 31:1515–1521.View ArticlePubMedGoogle Scholar
  23. Moore PE, Church TL, Chism DD, Panettieri RA Jr, Shore SA: IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Am J Physiol Lung Cell Mol Physiol 2002, 282:L847-L853.View ArticlePubMedGoogle Scholar
  24. Peng Q, Matsuda T, Hirst SJ: Signaling pathways regulating interleukin-13-stimulated chemokine release from airway smooth muscle. Am J Respir Crit Care Med 2004, 169:596–603.View ArticlePubMedGoogle Scholar
  25. Wen FQ, Liu X, Manda W, Terasaki Y, Kobayashi T, Abe S, Fang Q, Ertl R, Manouilova L, Rennard SI: TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol 2003, 111:1307–1318.View ArticlePubMedGoogle Scholar
  26. Chiquet-Ehrismann R, Tucker RP: Connective tissues: signalling by tenascins. Int J Biochem Cell Biol 2004, 36:1085–1089.View ArticlePubMedGoogle Scholar
  27. Ohkawara Y, Yamauchi K, Maruyama N, Hoshi H, Ohno I, Honma M, Tanno Y, Tamura G, Shirato K, Ohtani H: In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: in vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. Am J Respir Cell Mol Biol 1995, 12:4–12.View ArticlePubMedGoogle Scholar
  28. Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M: CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 2003, 111:1032–1040.View ArticlePubMedGoogle Scholar
  29. Grunstein MM, Hakonarson H, Leiter J, Chen M, Whelan R, Grunstein JS, Chuang S: IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002, 282:L520-L528.View ArticlePubMedGoogle Scholar
  30. Morse B, Sypek JP, Donaldson DD, Haley KJ, Lilly CM: Effects of IL-13 on airway responses in the guinea pig. Am J Physiol Lung Cell Mol Physiol 2002, 282:L44-L49.View ArticlePubMedGoogle Scholar
  31. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993, 12:2663–2670.PubMedPubMed CentralGoogle Scholar
  32. Zheng T, Zhu Z, Liu W, Lee CG, Chen Q, Homer RJ, Elias JA: Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol 2003, 111:720–728.View ArticlePubMedGoogle Scholar

Copyright

© Syed et al. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement